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ABSTRACT
Introduction. We recently reported six cases of pulmonary/hilar 
malignancies as the result of incidental findings (IF) on CT attenu-
ation correction (CTAC) during Single Photon Emission Computed 
Tomography Myocardial Perfusion Imaging (SPECT-CT MPI). In 
this study, clinical features, diagnostic procedures, and clinical 
outcomes were examined on all patients who had malignancies or 
significant IF that required further follow-up.
Methods.xOf 1,098 consecutive patients who underwent cardiac 
SPECT-CT MPI from September 1, 2017 to August 31, 2018, their 
MPI and CTAC were reviewed contemporaneously. Patients with 
known history of prior pulmonary or chest malignancy were excluded. 
Results. A total of 79 (7.2%) patients were identified to have sig-
nificant IF on CTAC. After diagnostic CT, 47 patients had significant 
findings that warranted further follow-up and included in this study. 
Eight of 1,098 patients (0.73%) and 8/79 patients (10.1%) were found 
to have malignancy of the chest because of IF on the CTAC. There 
were no statistically significant differences in baseline characteris-
tics and cancer risk factors among patients who had cancer versus 
those without. At the time of diagnosis, four patients had cancer at 
an advanced stage, resulting in death within 12 months. Three others 
had early stage lung cancer and one had mantle cell lymphoma; they 
were alive at a mean follow-up of 17.5+/-2.1 months. Biopsy for tissue 
diagnosis was performed safely with needle biopsy. Major complica-
tion occurred in one patient (1/9 or 11.1%) with needle biopsy; none 
with surgical biopsy.
Conclusion. This study underscored the importance of reviewing 
CTAC images obtained during cardiac SPECT-CT MPI to detect 
clinically important IF. Kans J Med 2020;13:280-284
INTRODUCTION
Myocardial perfusion imaging (MPI) using single photon emission 
CT (SPECT) may subject to artifacts.1,2 These artifacts can mimic 
myocardial perfusion defects leading to false-positive results. To 
improve image quality, low-dose, low-resolution CT attenuation cor-
rection (CTAC) are used commonly for anatomical correction and 
artifact attenuation during SPECT MPI. The CT scan is performed 
through the area of the chest, which is aligned with the SPECT scan 
of the heart. CT images are thus a by-product of the attenuation cor-
rection process.
Compared with those of diagnostic CT studies, acquisition using 
a low tube current (mA) and large slice thickness results in images 
that have low signal-to-noise ratio and poor spatial resolution. Thus, 
the resulting images are adequate for the purpose for which they have 
been acquired, but are not considered to be diagnostic quality. Thus, 
they are labelled as “non-diagnostic” by the manufacturers. However, 
CTAC images often reveal incidental findings (IF); some of them are 
of clinical significance.3-5
Previously, we reported a series of six cases of lung/hilar malig-
nancy detected by CTAC during SPECT-CT MPI.6 In that report, a 
total of  73/1,098 (6.6%) patients were found to have significant IF of 
the chest that required further evaluation at the time of SPECT-CT 
MPI and 6/1,098 (0.55%) patients were found to have pulmonary/
hilar malignancy. 
The objective of this report was to determine the clinical char-
acteristics, diagnostic testing/procedures performed, and clinical 
outcome of all patients who were found to have malignancies or those 
with significant IF on CTAC that required further follow-up.
METHODS
The patient population, technical aspect of the SPECT-CT MPI, 
and protocol for imaging analysis were described previously.6 A ret-
rospective review of records was completed on 1,098 consecutive 
patients who underwent cardiac SPECT-CT MPI from September 
1, 2017 to August 31, 2018 at both campuses of Eastern Kansas VA 
HealthCare System. The results of MPI and CTAC were reviewed 
and reported contemporaneously after the study by one of the two 
radiologists, both of whom were experienced and board-certified in 
the American Board of Radiology. They were blinded to patients’ clin-
ical information except the indication for the cardiac stress testing. In 
this study, significant IF were defined as suspicious lesions of poten-
tial malignancy of the lung or chest. There were 79 patients who were 
found to have significant IF by CTAC that required further evaluation 
by a diagnostic chest CT. After diagnostic chest CT, 32 patients were 
found to have benign findings that warranted no further follow-up; 47 
patients were included in this report. Patients with known history of 
prior pulmonary or chest malignancy were excluded. 
For tissue diagnosis, either needle or surgical biopsy were per-
formed. The core needle biopsy (CNB) was performed under 
CT-guidance by radiologists, endoscopic bronchial ultrasound guided 
fine needle aspiration (EBUS FNA) by a pulmonologist, and surgi-
cal biopsy by surgeons.  For patients who required further follow-up, 
the interval and duration of chest CT for follow-up were determined 
according to the Fleischner Society 2017 guidelines.7 All patients had 
follow-up of at least 12 months in duration; follow-up information was 
obtained by reviewing patient medical records. 
Statistical Analysis. Nominal values were expressed as numbers, 
percentages, and variables expressed as mean +/- standard devia-
tions. The baseline characteristics of patients with and without cancer 
were compared. Variable analysis was performed using Chi-square 
estimates and differences were considered statistically significant for 
p value of < 0.05.
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RESULTS
The patients’ baseline characteristics such as age, gender, and 
cancer risk factors are summarized in Table 1. When baseline char-
acteristics and some cancer risk factors, including smoking exposure, 
personal history or family history of cancer, were compared, no statis-
tical differences were observed between the groups of patients with 
or without cancer using univariate and multivariate analysis. History 
of past or current smoking also was found not to be an independent, 
significant factor in this study, likely due to more than 80% of patients 
in both groups who had smoking exposure. Only when age greater 
than 60 years, history of cancer, and family history of cancer were 
combined, a borderline, but statistical significance, was detected in 
the group of patients with malignancy (p = 0.049 by Chi-square esti-
mates). However, this result needs to be interpreted with caution 
due to the small number of patients in the study. All patients (n = 
47) were followed up for at least one year with a mean of 16.4 ± 3.9 
months, ranged 12 - 23 months. Among these 47 patients, only five 
(10.6%) had no diagnostic CT despite recommendation; the rest had 
a mean of 1.76 ± 0.68 CTs (range: one to three CTs) during follow-up. 
The majority of patients had one to two CTs (one CT in 16 patients, 
two CTs in 20 patients); only six patients had more than three CTs. 
Fourteen patients had Positron Emission Tomography (PET).
Table 1. Patient's baseline characteristics and cancer risk 
factors. 
All patients 
(%; n = 47)
Patients 
without 
cancer 
(%; n = 39)
Patients with 
cancer 
(%; n = 8)
p value
Age (mean), 
years 69.4+7.8 69.1 ± 8.5 71.0 ± 3.7 0.32
Male gender 46 (97.9) 38 (97.4) 8 (100) NS*
History of 
smoking 38 (80.9) 30 (76.9) 8 (100) 0.131
History of 
cancer 10 (15.1) 7 (17.9) 3 (37.5) 0.234
Family 
history of 
cancer
16 (34.0) 12 (30.8) 4 (50.0) 0.663
*NS = not significant.
Besides the malignancy detected in our previously reported 
patients,6 two additional patients were found to have cancer, includ-
ing lung cancer in one patient (Figure 1) and malignant mesothelioma 
in the other (Figure 2). This case of lung cancer was diagnosed clini-
cally (Table 2, case #8). Due to severe bullous emphysema and the 
location of the lung mass, the patient was referred to a tertiary uni-
versity-based medical center for CNB. The CNB was negative for 
cancer, but complication with pneumothorax required chest tube 
placement. At six months follow-up, this patient’s pulmonary nodule 
was increased in size from 6x8 mm to 10x7 mm on CT and SUV 
(Standard Uptake Value) on PET increased from 0.9 to 3.9. Because 
the risk for either a repeat CNB or surgical biopsy was considered 
clinically prohibitive, the patient was referred to oncology for evalu-
ation. This patient was diagnosed with Stage 1A non-small cell lung 
cancer, for which he received stereostatic ablative radiotherapy. Thus, 
the incidence of malignancy of chest in our patients who underwent 
cardiac SPECT-CT MPI was 0.73% (8/1,098 patients) and 10.1% 
(8/79 patients) among those with IF on CTAC.
At the time of diagnosis of malignancy, four patients were found 
to have cancer at an advanced stage: three patients had lung cancer 
≥ stage III, and one had locally invasive, nonresectable malignant 
mesothelioma. All of them died within 12 months after initial abnor-
mal CTAC (mean 11.5 ± 0.5 months). The rest (four) were found to 
have early stages of lung cancer or lymphoma and were all alive at 
the last follow-up (mean 17.5 ± 2.1, ranging 15 - 20 months; Table 2). 
At the end of follow-up, 43 of 47 patients were alive, including those 
five patients who did not have diagnostic chest CT as recommended.
Figure 1. Images of lung cancer (Case #8). A: Initial image from CTAC; B: 
Chest CT image showing left lower lobe spiculated mass measured at 6x8 mm; 
C: Follow-up CT image, mass measured at 10x7 mm. Arrow points at the mass.
Figure 2. Images of malignant mesothelioma (Case #7). A: Initial image from 
CTAC; B: Chest CT; C: PET scan. Abbreviation: CT – computed tomography; 
CTAC – CT attenuation correction; PET – Positron Emission Tomography. 
Arrow points at the mass.
A B
C
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C
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Table 2. Baseline characteristics, CTAC, diagnosis, and follow-up of patients with malignancy. 
Case # Gender Age, years
Smoking history
CTAC 
findings CT findings Diagnosis Staging
Follow-up, 
monthsPack, 
years
Stop in 
years
1 M 73 30 22
RUL 
2.6 cm, 
spiculated
RUL 
2.7 x 2.8 x 2.6 cm 
mass/
bronchogram
Squamous cancer Stage IB
Alive,
16
2 M 72 27 32 Subcarinal mass
4.5 x 8.2 x 10 cm
subcarinal mass Mantle cell lymphoma ---
Alive,
15
3 M 71 20 30
LLL 
1.6 cm 
density
LLL
1.6 cm spiculated
Invasive moderately
differentiated 
adenocarcinoma
Stage IA
Alive,
14
4 M 75 > 100 Current
RUL 
2.5 cm 
spiculated
RUL 
2.4 x 2.3 cm spiculated
Mixed adeno- squamous 
cancer Stage IIIB
Died,
11
5 M 64 > 50 Current
LUL 
0.9 cm 
nodule
LUL 
2.7 x 3.1 cm nodule
Poorly differentiate 
adenocarcinoma Stage IIIA
Died,
12
6 M 75 50 5 RLL density
RLL 
1.1 x 3.9 cm mass/
pleural based 
metastasis
Small cell cancer Stage IV
Died,
11
7 M 68 20 9
R 
pleural 
thickening
R pleural, nodular 
thickening
Malignant pleural 
mesothelioma Unresectable
Died,
12
8 M 70 60 Current
LML 
6 mm 
density
LLL
8 x 6 mm spiculated Non-small cell cancer Stage IA
Alive,
19
Abbreviations: CTAC: Computed Tomography Attenuation Correction; LLL: Left Lower Lobe; LUL: Left Upper Lobe; RLL: Right Lower Lobe; RUL: Right 
Upper Lobe.
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Thirteen (13/42, 31.0%) patients had tissue biopsy, including 
nine needle biopsies (one required subsequent surgical biopsy), 
and four surgical, including one axillary lymph node biopsy. Of nine 
patients who had needle biopsy, CT-guided CNB was performed in 
seven patients at our institute, one elsewhere, and EBUS FNA by a 
pulmonologist in one patient. Four of the needle biopsies revealed 
negative findings, including one patient who had subsequent surgi-
cal biopsy of a pleural based malignant mesothelioma (Figure 2). Of 
seven CNBs performed at our institution, only minor complications 
occurred in four patients (one had mild hemoptysis, pulmonary 
hemorrhage, and a tiny pneumothorax, both detected by CT; one 
had tiny pneumothorax detected by CT; and two others had pul-
monary hemorrhage by CT). None required any intervention. One 
high-risk patient had CNB elsewhere, which was complicated with 
pneumothorax requiring chest-tube placement. One other patient 
had EBUS FNA without complication. Thus, major complications 
occurred in one (11.1%) patient and minor ones occurred in four 
(44.4%) patients with needle biopsy. There was no complication 
with surgical biopsy.
DISCUSSION
The IF on CTAC during SPECT-CT MPI are frequent, but clini-
cally significant ones are relatively infrequent.3-5 The images obtained 
by low-dose, low resolution CTAC are adequate for the purpose 
for which they have been acquired (i.e., anatomical correction and 
artifact attenuation during cardiac MPI), but are not considered to 
be diagnostic quality. Despite the limitations of its quality, CTAC 
would detect pulmonary nodules/mass of certain sizes, as well as 
other abnormalities in the chest when reviewed. Currently among 
the nuclear cardiology community in the U.S., there is no uniform or 
consensus recommendations regarding reporting incidental findings 
during cardiac SPECT-CT MPI. Recommendations ranged from 
none8,9 to optional reporting10 or mandatory reporting.11,12 Since the 
majority of cardiac MPIs are reviewed and interpreted by nuclear 
cardiologists, the increased use of SPECT-CT during cardiac MPI 
give rise to the issue of reviewing and interpreting these CTAC 
images, as most nuclear cardiologists are not trained or skilled in CT 
interpretations. 
In this study, the main findings were: (1) IF by CTAC during 
SPECT-CT MPI might be of significant clinical implications, includ-
ing detection of malignancy; (2) prognosis of patients who were 
found to have cancer of advanced stage at the time of diagnosis was 
poor; and (3) when biopsies were performed for tissue diagnosis, 
they could be performed safely.
KANSAS JOURNAL of  M E D I C I N E
283
MALIGNANCY OF THE CHEST BY SPECT-CT MPI
continued.
Some studies showed IF were common, but clinically important 
ones infrequent,13-14 while others showed unclear cost-effectiveness 
in further diagnostic workup of pulmonary nodules among nonsmok-
ers.15,16 Recently, prognostic benefits from extracardiac incidental 
findings on CTAC during SPECT-CT MPI were observed.17,18 Even 
though IF did not significantly increase all-cause mortality, they were 
associated with a significantly higher cancer-specific mortality.17 
Furthermore, a study by Zadro et al.18 investigated the outcome of 
patients with significant incidental findings by CTAC during cardiac 
SPECT-CT MPI. They found that the prevalence of previously 
unknown extracardiac malignancies was 1%, similar to those reported 
by others.19 Their study showed that over a period of 3.2 ± 1.2 years 
of follow-up, among the patients with major extracardiac findings, 12 
(6.0%) died from cardiovascular versus 36 (17.9%) from neoplastic 
causes, reflecting a significant annual mortality rate of 1.9% versus 
5.6%, respectively, regardless of cardiac MPI findings.
In our study there was no significant difference in the clinical 
feature and certain cancer risk factors among groups of patients with 
or without cancer. Only when age of greater than 60 years, history of 
cancer, and family history of cancer were combined, a borderline sig-
nificance was detected in the group of patients with malignancy. The 
incidence of malignancy in patients with significant IF that required 
a diagnostic CT was 10.1% (8/79) or 0.73% (8/1098) of all patients. 
Therefore, all CTAC images during cardiac SPECT-CT should be 
reviewed routinely for significant IF which might lead to the detection 
of malignancy of the chest.
Lung cancer remains one of the leading cancers in our nation.20 
The  National Cancer Institute reported that lung cancer mortality 
rate remained high and five-year survival rate low.21 The low five-year 
survival rate is related directly to the stage of cancer at the time of 
diagnosis: Stage I - 55.1% (20.7% of cases); Stage II - 34.7% (4.6% 
of cases); Stage III - 15.8% (23.3% of cases), Stage IV - 4.2% (43.6% 
of cases). In that report, lung cancer (66.9%) was found mostly at 
Stage III - IV at the time of diagnosis. Therefore, early detection of 
lung cancer is important for improved survival. Clinically, low-dose 
CT was used for early detection/screening of lung cancer in high risk 
patients22 and was associated with reduced lung-cancer and any cause 
mortality in National Lung Screening Trial.23 Currently, low-dose CT 
is recommended for lung cancer screening of high-risk patients by 
U.S. Preventive Service Task Force (USPSTF).24  
The intention of our study was not to screen for lung cancer, but 
rather to review readily available CTAC during MPI for significant 
IF of the chest. Despite the low-resolution of CTAC, which might 
miss lung cancer of smaller sizes, we detected chest malignancy in 
0.73% (8/1,098) of patients, the majority of which were lung cancer 
(6/8 or 75%). Our study also showed that the prognosis for patients 
with cancer of advanced stage was very poor: all four patients with 
lung cancer (n = 3) or mesothelioma (n = 1) of advanced stages at the 
time of diagnosis died during a mean follow-up of 11.5 ± 0.5 months, 
while the other four patients with lung cancer of earlier stages or lym-
phoma remained alive during a mean follow-up of 17.5 ± 2.1 months. 
By reviewing all CTACs for IF during cardiac SPECT-CT MPI, it 
allowed us to detect these chest malignancies that otherwise would 
be not detected. That, in turn, might offer some of those patients an 
opportunity for early cancer detection and improved survival.
When significant IF were found, further diagnostic CT, PET scan, 
or biopsies were used for investigation. Besides five patients who had 
no chest CT despite recommendation, the majority of patients had 
one to two CTs; only six patients had greater than three CTs as the 
interval and duration of chest CT were determined according to the 
Fleischner Society 2017 guidelines.7 The effects of radiation from 
follow-up CT could not be determined in this study. When biopsy 
was needed for tissue diagnosis, CT-guided lung biopsy commonly 
was performed. Complications of lung biopsy were classified as major 
or minor according to the Society of Interventional Radiology (SIR) 
Guidelines.25 Major complications of needle lung biopsy consisted 
of pneumothorax requiring intervention, hemothorax, air embolism, 
needle tract seeding, and death. Minor complications consisted of 
pneumothorax without need for intervention, ground glass opacity 
around the target diagnosed as pulmonary hemorrhage, and transient 
hemoptysis. For CT-guided CNB or FNB, the major complication 
rate was low while minor ones were common.26 In our study, only one 
major complication occurred with needle biopsy of nine patients and 
minor complications occurred in four patients. No complication was 
observed with surgical biopsy. In our small number of patients, lung 
needle biopsies were performed safely.
CONCLUSIONS
Our present study and other recent reports17,18 underscored the 
guideline’s recommendation11,12 to review all CTAC images obtained 
during cardiac SPECT-CT MPI to detect clinically important IF that 
might have impact on patients’ survival with reasonable low risks of 
physical harm from additional testing.
LIMITATIONS
The study was retrospective and small in the number of patients 
with short follow-up duration of a mean 16 months. Small numbers 
of patients with IF on CTAC had no chest CT examination despite 
recommendation. There were obvious limitations of CTAC used for 
its intended purposes, that included its low resolution, respiratory 
motion artifacts, and that they were not of the whole chest. Therefore, 
small and apical lesions could have been missed. However, both sets 
of CT at rest and after stress were reviewed to reduce or minimize 
the effects of respiratory motion artifacts. Thus, the true prevalence 
or incidence of malignancy of the chest could be higher as reported 
here. Potential harm of radiation exposure and mental stress from the 
diagnosis of these IF could not be assessed by this study.
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